Company Profile
Eagle Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Eagle Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Eagle Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Eagle Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Eagle Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
EGRX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Eagle’s catalysts are hospital-product execution and any portfolio update that clarifies the company’s growth path. The market cares about recurring demand and margin discipline.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan
Source: Eagle Pharmaceuticals
- 02
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties
Source: Eagle Pharmaceuticals
- 03
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
Source: Eagle Pharmaceuticals
- 04
Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors
Source: Eagle Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.